# Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

> **NCT05472623** · PHASE2 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Resectable Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Adagrasib
- **COMBINATION_PRODUCT:** Adagrasib/Nivolumab

## Key facts

- **NCT ID:** NCT05472623
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-21
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** no participants enrolled across sites
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05472623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05472623, "Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05472623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*